Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 20Neoplasms 9Neoplasm Metastasis 5Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 1Solid Tumors 1Solid Malignancies 1Recurrence 1Pancreatic Neoplasms 1Lung Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma 1Advanced Solid Tumors 1Adenocarcinoma Of Esophagus 1

Interventions

Paclitaxel 12atezolizumab 11Gemcitabine 9pembrolizumab 8Injections 6Carboplatin 6Irinotecan 5Docetaxel 5Cetuximab 5tocilizumab 4navitoclax 4Leucovorin 4Fluorouracil 4Bevacizumab 4olaparib 3cobimetinib 3Oxaliplatin 3Nivolumab 3zolbetuximab 2tumor necrosis factor-alpha, CNGRC fusion protein, human 2tivozanib 2tislelizumab 2spartalizumab 2ridaforolimus 2plocabulin 2obinutuzumab 2motesanib diphosphate 2liposomal doxorubicin 2linifanib 2lenvatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Solid Tumors × ixabepilone × Clear all
NCT01018966 2017-01-30

Study of Ixabepilone (BMS-247550) in Patients With Solid Tumors

R-Pharm

Phase 1 Completed
25 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡